Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cost Plus Drugs vs TrueMe

Cost Plus Drugs
Graded #370

Lower grade

vs+9.099999999999994
TrueMe
Graded #163

Higher grade

The verdict

TrueMe takes it — 67.6/100 to 58.5/100.

TrueMe grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TrueMe is a cash-pay telehealth brand offering compounded semaglutide and tirzepatide with added B vitamins, alongside NAD+, sermorelin and glutathione.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrueMe +17
45
62
Dose & formulationTrueMe +12
65
77
Clinical oversightTrueMe +11
67
78
Labs & monitoringTrueMe +1
51
52
FulfillmentTrueMe +8
73
81
Contract termsCost Plus Drugs +10
55
45
Cost Plus Drugs · left barTrueMe · right bar

The numbers

MetricCost Plus DrugsTrueMe
WeighScore58.5/10067.6/100
GradeCC
Scorecard rank#370#163
Semaglutide$279/mo (brand Ozempic)$159/mo (compounded)
TirzepatideNot disclosed$189/mo (compounded)
CoverageAll 50 states6 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Cost Plus Drugs

Graded #370 · C

Strengths

  • Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
  • Around $279/mo for branded Ozempic — well below typical retail list prices
  • Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
  • Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
  • Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing

Where it loses points

  • Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
  • Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
  • Wegovy availability has been spotty — check current stock before assuming it ships
  • No compounded semaglutide or tirzepatide — brand only
  • No clinical follow-up — side-effect monitoring falls to your prescribing clinician
TrueMe

Graded #163 · C

Strengths

  • One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
  • Same price at every dose, so the cost does not climb as a provider titrates the dose upward
  • Full pricing is published up front — no intake form is required before you can see what you will pay
  • Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
  • Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas

Where it loses points

  • Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
  • Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
  • You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
  • The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
  • A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard